title: [Treatment of gastric cancer].
abstract: From a global perspective, gastric cancer including adenocarcinoma of the esophagogastric junction is the fourth most common malignant tumor and the second most common cause of cancer-related death. Due to the lack of specific symptoms of early cancer, most gastric cancers are diagnosed in advanced stages. Staging should include high-resolution computed tomography of the thorax, abdomen, and pelvis and documented video-endoscopy and endoscopic ultrasound. In mucosal gastric cancer, endoscopic resection can replace surgical resection. In more advanced stages, perioperative chemotherapy has been established as a standard of care. In the metastatic setting, treatment goals are palliative. Chemotherapy can prolong survival, improve symptoms, and enhance the quality of life. Combination chemotherapy including a platinum salt plus fluoropyrimidine is the standard of care. About 16 % of gastric cancers exhibit overexpression of the growth factor receptor HER2. Trastuzumab has shown to prolong survival when combined with chemotherapy in HER2-positive gastric cancer.
authors.affiliation: Universitäres Krebszentrum Leipzig, Universitätsklinikum Leipzig AöR, Liebigstr. 20, 03401, Leipzig, Deutschland, florian.lordick@medizin.uni-leipzig.de.
authors.forename: F
authors.initials: F
authors.lastname: Lordick
authors.forename: A
authors.initials: A
authors.lastname: Hoffmeister
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D059248:Chemoradiotherapy / Q000379:methods*; D003131:Combined Modality Therapy / Q000379:methods; D016099:Endoscopy, Gastrointestinal / Q000379:methods*; D005743:Gastrectomy / Q000379:methods*; D006801:Humans; D009367:Neoplasm Staging; D013274:Stomach Neoplasms / Q000473:pathology* / Q000628:therapy*